The Recall Desk
ModerateFDA (Drugs)·D-0588-2026·Announced 2026-06-24

Alyacen 7/7/7 birth control tablets failed total impurities specification

Alyacen 7/7/7 norethindrone and ethinyl estradiol tablets are being recalled because of out-of-specification results for total impurities.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: FDA Class II recall for an out-of-specification impurities result with no named impurity or clinical consequence described, which fits the Moderate band.

Plain-English summary

Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/0.035 mg, 0.75 mg/0.035 mg and 1 mg/0.035 mg, supplied as three blister cards of 28 tablets for a 28-day regimen, prescription only, manufactured by Glenmark Pharmaceuticals Ltd., is being recalled.

The stated reason is failed impurities and degradation specifications: the recall was initiated due to out-of-specification results for total impurities. The FDA classified the action as Class II. The source does not describe a resulting clinical consequence.

Affected lots are 20240411 (expiring 6/30/2026) and 20250252 (expiring 3/31/2027). Distribution was USA nationwide.

Patients should not stop taking a prescribed medicine without advice. Anyone holding an affected lot should speak to their pharmacist or prescriber and follow the instructions issued by the firm.

The recalled product

Product
ALYACEN 1/35 (NORETHINDRONE AND ETHINYL ESTRADIOL)
Brand
ALYACEN 1/35

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot #: 20240411
  • Exp: 6/30/2026
  • 20250252
  • Exp: 3/31/2027

UPCs (3)

  • 0368462394847
  • 0368462394298
  • 0368462556849

Distribution

Distributed nationwide across the United States.